PGH
ESPR

Partners Group Holding’s Esperion Therapeutics ESPR Stock Holding History

Partners Group Holding’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9,312
Closed -$613K – 51
2017
Q4 		$613K Buy
+9,312
New +$501K 0.07% 41

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Partners Group Holding's ESPR Position: Q1 2018 in Review

Partners Group Holding sold out of Esperion Therapeutics (ESPR) in Q1 2018, closing a stake of 9,312 shares — an estimated $613K sold.

Partners Group Holding first reported a position in ESPR in Q4 2017 and held it in 1 quarter. The position peaked at $613K in Q4 2017. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

  • Partners Group Holding reported no remaining Esperion Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Partners Group Holding sold 9,312 Esperion Therapeutics shares in Q1 2018, an estimated $613K.
  • Partners Group Holding first reported a position in Esperion Therapeutics in Q4 2017 and held it in 1 quarter.
  • Partners Group Holding's Esperion Therapeutics position peaked at $613K in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Partners Group Holding's 13F filing for Q1 2018, filed 11 May 2018.